Skip to content
Search

Latest Stories

Smith & Nephew names Deepak Nath as CEO

Medical devices maker Smith & Nephew has appointed Siemens Healthineers' Deepak Nath as chief executive, replacing Roland Diggelmann after the company narrowly missed analysts' estimate for annual profit.

Diggelmann was brought in after the company's former boss left over pay in late 2019, and the British firm was counting his more than 20 years' experience in the orthopaedics and diagnostics sectors to accelerate its revenue growth.


However, the pandemic hit soon after, forcing hospitals to delay elective surgeries and services to accommodate Covid-19 patients, and hitting demand for the company's hip and knee replacements while supply chain issues also weighed it down.

Smith & Nephew said Diggelmann was leaving “by mutual agreement” on March 31.

Revenue at the British company rose 10.3 per cent to $5.21 billion in the 12 months ended Dec. 31 on an underlying basis, steadily recovering from 2020, while trading profit came in at $936 million, compared with $683 million in the previous year.

Healthcare networks globally are under pressure again by the new Omicron coronavirus variant, and the company is targeting underlying revenue growth in the range 4.0 to 5.0 per cent for 2022.

Nath, who was previously president of diagnostics at Siemens, will start at Smith & Nephew from April 1.

"(Deepak Nath) is joining us at an inflection point for the business and will bring his drive, experience and expertise to lead the team in delivering our Strategy for growth at pace," chairman Roberto Quarta said in a statement.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less